New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
09:16 EDTAAN, MS, POT, JNJ, PESI, INFY, ZBRA, KO, HALO, BHP, MSIOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Coca-Cola (KO), up 2.2%... Johnson & Johnson (JNJ), up 2.1%. ALSO HIGHER: Zebra Technologies (ZBRA), up 5.5% after agreeing to acquire Motorola Solution's (MSI) enterprise unit for $3.45B. Motorola Solutions shares are up 3.5% following the news... Halozyme (HALO), up 8.5% after initiated with Buy rating at Citigroup... Potash (POT), up 2.3% after Globe & Mail says the company is speculated to be targeted again by BHP Billiton (BHP)... Morgan Stanley (MS), up 2% after upgraded at BofA Merrill Lynch. DOWN AFTER EARNINGS: Infosys (INFY), down 2.5%... Perma-fix (PESI), down 8.9%. ALSO LOWER: Aaron's (AAN), down 5% after cuttings Q1 EPS and revenue guidance, acquiring Progressive Finance Holdings for $700M, and rejecting Vintage Capital's takeover offer.
News For KO;JNJ;MSI;ZBRA;POT;BHP;INFY;MS;HALO;PESI;AAN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 13, 2015
17:50 EDTJNJPharmacyclics to showcase new 'promising' Imbruvica data at ASCO
Pharmacyclics announced that ibrutinib, also known as Imbruvica, single-agent and combination data will be featured in seven oral and poster sessions at the 51st American Society of Clinical Oncology, ASCO, Annual Meeting being held May 29-June 2 in Chicago, IL. According to a statement from ASCO, Imbruvica data will also be included in the official press program during the meeting for the second time in two years. Imbruvica is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a Johnson & Johnson (JNJ) subsidiary. Data being presented include, among others, an oral presentation from the Phase III HELIOS study of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia, a poster presentation of ibrutinib in steroid-dependent or refractory chronic graft-versus-host-disease as well as a dose adherence analysis of ibrutinib 420 mg administered to previously treated CLL patients. "We look forward to sharing promising data at this year's ASCO that examines the use of Imbruvica across a broad range of hematologic disease settings from our clinical studies," said Danelle James, M.D., M.S., Head of Oncology at Pharmacyclics.
16:50 EDTKOCoca-Cola Bottling signs LOI for major expansion of franchise territories
Coca-Cola Bottling (COKE) announced that it has signed a non-binding letter of intent with The Coca-Cola Company (KO) to further expand the company's franchise territory. The transactions proposed in the letter of intent would provide exclusive distribution rights for the company in territories located within Delaware, the District of Columbia, Illinois, Indiana, Kentucky, Maryland, North Carolina, Ohio, Pennsylvania, Virginia and West Virginia. This additional territory would include the following major markets: Baltimore, MD; Alexandria, Norfolk and Richmond, VA; Cincinnati, Columbus and Dayton, OH; Indianapolis, IN and Washington, D.C. Coca-Cola Refreshments USA, a wholly owned subsidiary of The Coca-Cola Company, currently serves these territories. The Company recently completed an expansion of its franchise distribution territory by acquiring sub-bottling distribution rights from CCR in parts of Tennessee, Kentucky and Indiana and continues to integrate these new territories which include major markets in Knoxville, TN, Louisville and Lexington, KY and Evansville, IN. The transactions proposed in the letter of intent are subject to the parties reaching a definitive agreement, with territory expansion closings expected to begin in the fall of 2015. There is no assurance, however, that any definitive agreement will be reached or that the closings of the proposed territory expansion transactions will occur.
16:17 EDTKOCoca-Cola announces letters of intent with two U.S. bottling partners
The Coca-Cola Company has agreed in principle to grant additional expanded territories to Coca-Cola Bottling Co. Consolidated, which will assume markets in Delaware, the District of Columbia, Illinois, Indiana, Kentucky, Maryland, North Carolina, Ohio, Pennsylvania, Virginia and West Virginia. Additionally, The Coca-Cola Company has agreed in principle to grant expanded territories to a new expanding U.S. bottler, Clark Beverage Group, which will assume markets in Mississippi. “As we’ve shared before, we continue to align our U.S. operations with highly capable partners of all sizes that have consistently invested for growth,” said Sandy Douglas, President, Coca-Cola North America. “The announcement today with Coca-Cola Bottling Co. Consolidated and Clark Beverage Group reinforces our successful efforts to move forward with our refranchising plans in the U.S. as we implement a more agile, modern, customer-focused beverage partnership model.”
09:32 EDTMSMorgan Stanley fined $2M by FINRA for short interest reporting, rule violations
FINRA announced that it has fined Morgan Stanley & Co. LLC $2M for short interest reporting and short sale rule violations that spanned a period of more than six years, and for failing to implement a supervisory system reasonably designed to detect and prevent such violations. FINRA found that Morgan Stanley, over several years, failed to completely and accurately report its short interest positions in certain securities involving billions of shares. FINRA also found that the firm's supervisory system was deficient because it failed to detect and prevent these violations over an extended period of time. FINRA found that over a seven-year period, Morgan Stanley included positions from the accounts of non-broker-dealer affiliates in a number of aggregation units when determining each unit's net position. FINRA also found that the firm's supervisory system was not reasonably designed to detect and prevent such violations. In concluding this settlement, Morgan Stanley neither admitted nor denied the charges, but consented to the entry of FINRA's findings.
06:29 EDTZBRAZebra Technologies sees Q2 EPS $1.00-$1.25, consensus $1.17
Subscribe for More Information
06:28 EDTZBRAZebra Technologies reports Q1 EPS $1.39 consensus $1.12
Subscribe for More Information
May 12, 2015
15:00 EDTZBRANotable companies reporting before tomorrow's open
Subscribe for More Information
14:13 EDTMSBove says it may be time to buy bank stocks
Subscribe for More Information
09:14 EDTKOApps World to hold a conference
Subscribe for More Information
07:48 EDTMSStandard & Poor's to hold a summit
Subscribe for More Information
07:28 EDTKOMonster Beverage deal financials better than expected, says JPMorgan
Subscribe for More Information
May 11, 2015
17:58 EDTJNJJ&J's Janssen gets complete response letter regarding sNDA for Invega Sustenna
Subscribe for More Information
17:39 EDTINFYInfosys refocuses on top clients, Economic Times says
Subscribe for More Information
17:02 EDTMSMorgan Stanley to sell Global Oil Merchanting unit to Castleton Commodities
Subscribe for More Information
16:42 EDTHALOHalozyme sees FY15 revenue $85M-$95M, consensus $93.34M
Subscribe for More Information
16:41 EDTHALOHalozyme reports Q1 EPS (12c), consensus (13c)
Subscribe for More Information
15:00 EDTHALONotable companies reporting after market close
Subscribe for More Information
12:51 EDTMSOn The Fly: Top stock stories at midday
Subscribe for More Information
08:18 EDTMSBanks executives seek to push back on 'false, damaging' statements, WSJ reports
Subscribe for More Information
07:07 EDTMSMorgan Stanley announces sale of Creative Circle to On Assignment
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use